Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $24.43

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have received an average recommendation of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $24.43.

Several research firms have recently weighed in on TEVA. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Finally, UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. lifted its holdings in Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. Asset Management One Co. Ltd. lifted its holdings in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after buying an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock worth $23,368,000 after buying an additional 1,045,305 shares in the last quarter. Finally, Capital Wealth Planning LLC lifted its holdings in Teva Pharmaceutical Industries by 8.8% during the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company’s stock worth $5,435,000 after buying an additional 20,016 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 1.6%

Shares of TEVA opened at $16.75 on Friday. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $18.99 billion, a price-to-earnings ratio of -11.55, a P/E/G ratio of 1.44 and a beta of 0.62. The stock’s 50-day moving average price is $15.36 and its 200 day moving average price is $17.39.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the previous year, the business earned $0.48 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, research analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.